We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Zacks Analyst Blog Highlights Linde, Vertex Pharmaceuticals, Edwards Lifesciences, General Motors and MSCI
Read MoreHide Full Article
For Immediate Release
Chicago, IL – April 24, 2023 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Linde plc (LIN - Free Report) , Vertex Pharmaceuticals Inc. (VRTX - Free Report) , Edwards Lifesciences Corp. (EW - Free Report) , General Motors Co. (GM - Free Report) and MSCI Inc. (MSCI - Free Report) .
Here are highlights from Friday’s Analyst Blog:
Top Stock Reports for Linde, Vertex Pharmaceuticals and Edwards Lifesciences
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Linde plc, Vertex Pharmaceuticals Inc. and Edwards Lifesciences Corp. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
Linde’s shares have outperformed the Zacks Chemical - Specialty industry over the past year (+20.4% vs. -1.6%). The company is making the world more productive by the day, with its wide range of applications for industrial gases. Linde’s primary products in industrial gases include oxygen, which is used as life support in hospitals. Its process gas, like hydrogen, is being utilized for clean fuels, while its high-purity and specialty gases are employed to manufacture electronics.
Linde has long-term contracts with on-site customers backed by minimum purchase requirements, thereby securing stable cashflows. In the profitable industrial gas market, the merger of Praxair and Linde has created an efficient player with considerable size advantages.
However, the cost of sales continues to increase, hurting the firm’s bottom line. The firm has mostly been paying a lower dividend yield than the industry’s composite stocks over the past two years.
Shares of Vertex Pharmaceuticals have outperformed the Zacks Medical - Biomedical and Genetics industry over the past year (+21.7% vs. -7.0%). The company’s cystic franchise sales continue to grow driven by its triple therapy, Trikafta/Kaftrio. New reimbursement agreements in ex-U.S. markets and label expansions to younger age groups are driving Trikafta/Kaftrio sales higher.
Vertex has reported double-digit revenue growth over the last several years. It has a broad clinical non-CF pipeline across six disease areas, which are progressing rapidly with multiple clinical milestones in 2023. Multiple late-stage projects have established proof of concept. Vertex faces only minimal competition in its core CF franchise.
However, Vertex’s dependence on just the CF franchise for commercial revenues is a concern. Vertex’s non-CF programs carry significant risk, which is a concern.
Shares of Edwards Lifesciences have outperformed the Zacks Medical - Instruments industry over the year-to-date period (+14.9% vs. +4.8%). The company’s TMTT segment registered strong growth driven by the continued adoption of the PASCAL platform in Europe.
Further, the growth within Surgical Structural Heart was lifted by increased adoption of the company's premium RESILIA technologies around the world, including the recent launch of the company's MITRIS surgical mitral valve.
Moreover, the expansion of both margins is encouraging. However, during the quarter, TAVR procedure volumes were impacted by the U.S. hospital staffing constraints and the holiday season slowdown.
Other noteworthy reports we are featuring today include General Motors Co. and MSCI Inc.
Why Haven’t You Looked at Zacks' Top Stocks?
Since 2000, our top stock-picking strategies have blown away the S&P's +6.2 average gain per year. Amazingly, they soared with average gains of +46.4%, +49.5% and +55.2% per year. Today you can access their live picks without cost or obligation.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
The Zacks Analyst Blog Highlights Linde, Vertex Pharmaceuticals, Edwards Lifesciences, General Motors and MSCI
For Immediate Release
Chicago, IL – April 24, 2023 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Linde plc (LIN - Free Report) , Vertex Pharmaceuticals Inc. (VRTX - Free Report) , Edwards Lifesciences Corp. (EW - Free Report) , General Motors Co. (GM - Free Report) and MSCI Inc. (MSCI - Free Report) .
Here are highlights from Friday’s Analyst Blog:
Top Stock Reports for Linde, Vertex Pharmaceuticals and Edwards Lifesciences
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Linde plc, Vertex Pharmaceuticals Inc. and Edwards Lifesciences Corp. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today’s research reports here >>>
Linde’s shares have outperformed the Zacks Chemical - Specialty industry over the past year (+20.4% vs. -1.6%). The company is making the world more productive by the day, with its wide range of applications for industrial gases. Linde’s primary products in industrial gases include oxygen, which is used as life support in hospitals. Its process gas, like hydrogen, is being utilized for clean fuels, while its high-purity and specialty gases are employed to manufacture electronics.
Linde has long-term contracts with on-site customers backed by minimum purchase requirements, thereby securing stable cashflows. In the profitable industrial gas market, the merger of Praxair and Linde has created an efficient player with considerable size advantages.
However, the cost of sales continues to increase, hurting the firm’s bottom line. The firm has mostly been paying a lower dividend yield than the industry’s composite stocks over the past two years.
(You can read the full research report on Linde here >>>)
Shares of Vertex Pharmaceuticals have outperformed the Zacks Medical - Biomedical and Genetics industry over the past year (+21.7% vs. -7.0%). The company’s cystic franchise sales continue to grow driven by its triple therapy, Trikafta/Kaftrio. New reimbursement agreements in ex-U.S. markets and label expansions to younger age groups are driving Trikafta/Kaftrio sales higher.
Vertex has reported double-digit revenue growth over the last several years. It has a broad clinical non-CF pipeline across six disease areas, which are progressing rapidly with multiple clinical milestones in 2023. Multiple late-stage projects have established proof of concept. Vertex faces only minimal competition in its core CF franchise.
However, Vertex’s dependence on just the CF franchise for commercial revenues is a concern. Vertex’s non-CF programs carry significant risk, which is a concern.
(You can read the full research report on Vertex Pharmaceuticals here >>>)
Shares of Edwards Lifesciences have outperformed the Zacks Medical - Instruments industry over the year-to-date period (+14.9% vs. +4.8%). The company’s TMTT segment registered strong growth driven by the continued adoption of the PASCAL platform in Europe.
Further, the growth within Surgical Structural Heart was lifted by increased adoption of the company's premium RESILIA technologies around the world, including the recent launch of the company's MITRIS surgical mitral valve.
Moreover, the expansion of both margins is encouraging. However, during the quarter, TAVR procedure volumes were impacted by the U.S. hospital staffing constraints and the holiday season slowdown.
(You can read the full research report on Edwards Lifesciences here >>>)
Other noteworthy reports we are featuring today include General Motors Co. and MSCI Inc.
Why Haven’t You Looked at Zacks' Top Stocks?
Since 2000, our top stock-picking strategies have blown away the S&P's +6.2 average gain per year. Amazingly, they soared with average gains of +46.4%, +49.5% and +55.2% per year. Today you can access their live picks without cost or obligation.
See Stocks Free >>
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
https://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.